NCT04691375: A Study of PY314 in Subjects With Advanced Solid Tumors

NCT04691375
Breast Cancer Type: HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: TREM
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 1
Drug Category: Immunotherapy, Therapeutic Antibody

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases: 
Additional Notes: Patients must have progressed on at least one line of metastatic therapy; Breast cancer patients with tumors that express TREM2 will also be eligible for the dose expansion phase of the study
Exclusions: Patients with unstable, symptomatic, uncontrolled brain metastases- see trial for details; Patients who are eligible and have not progressed on molecularly targeted therapy (e.g. drugs targeting EGFR, HER2, etc)
https://ClinicalTrials.gov/show/NCT04691375

Comments are closed.

Up ↑